Fennec Pharmaceuticals vs Nektar Therapeutics
Nektar Therapeutics is the larger business, with $55.2m of revenue in fiscal 2025 against $44.6m for Fennec Pharmaceuticals (1.2 times as much). Fennec Pharmaceuticals grew faster (-6.1% against -43.9%). Fennec Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -21.8% against -297.1%.
| Latest fiscal year | Fennec PharmaceuticalsFENC, 2025 | Nektar TherapeuticsNKTR, 2025 |
|---|---|---|
| Revenue | $44.6m | $55.2m |
| Revenue growth | -6.1% | -43.9% |
| Net income | −$9.7m | −$164m |
| Operating margin | — | -253.7% |
| Net margin | -21.8% | -297.1% |
| Return on equity | -65.8% | — |
| Free cash flow | −$12.5m | −$209m |
| Cash | $36.8m | $15.1m |
| Total debt | $19.4m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | 35 | 63 |
| Market value | $377m | $765m |
| Price vs our value range | — | — |
| Moat score | — | 18 (Weak) |
| Insider trades, 12 months | 0 buys, 19 sales | 0 buys, 16 sales |